Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery

Pre-registration (Pre-Surgery) Eligibility Criteria * Histologic documentation: Prior histologic diagnosis of GBM at first occurrence * Stage: First or second recurrence of GBM or gliosarcoma considered to be surgically resectable * Prior Treatment: * No radiotherapy within 90 days prior to pre-registration * No prior treatment with any anti-angiogenic agent targeting the VEGF pathway including but not limited to bevacizumab, cediranib, vandetanib, sunitinib, pazopanib, aflibercept, or sorafenib * No prior treatment with HSPPC-96 or other investigational immunotherapy * Must have received prior treatment with radiotherapy and temozolomide for histologically confirmed GBM at initial diagnosis * No tumor directed therapy for most recent progression * No prior Gliadel® wafers * No clinically significant cardiovascular disease: * Patients with a history of hypertension must be well controlled (\<150/90) on a regimen of antihypertensive therapy. * History of arterial thrombotic events within the past 6 months, including transient ischemic attack (TIA), cerebrovascular accident (CVA), peripheral arterial thrombus, unstable angina or angina requiring surgical or medial intervention in the past 6 months, or myocardial infarction (MI). Patients with clinically significant peripheral artery disease (i.e., claudication on less than one block), significant vascular disease (i.e., aortic aneurysm, history of aortic dissection) are not eligible. * Patients who have had…